Cognitive functions assessment of elderly patients with type 2 diabetes mellitus

Close metadata

OBJECTIVE

Comparative assessment of the cognitive status of persons over 60, depending on the presence or absence of type 2 diabetes mellitus (T2DM).

MATERIAL AND METHODS

The study included 193 patients, of which 93 had no T2DM and 100 had T2DM. The mean age of patients with T2DM was 73 [68; 78] years vs. 69.2 [64; 75] years in patients without T2DM. The cognitive function was assessed using the McNair and Kahn scale, with scores over 42 indicating cognitive dysfunction and Kahn scale: in the group with T2DM, the average score was 27.0±9.36; in the group without T2DM, it was 22.0±9.60 (p<0.043). The absence of T2DM was negatively correlated with the total score on the scale for assessing the risk of cognitive impairment (p=–0.264, p<0.001). In addition, it was found that age over 75 years was significantly associated with the development of cognitive impairment, regardless of the presence of concomitant T2DM (OR=1.247, CI=95%, 1.112—1.40, p<0.001).

CONCLUSION

T2DM increases the risk of developing cognitive dysfunction, which should be taken into account in older patients for the timely detection and prevention of its progression.

Keywords:

diabetes mellitus

cognitive dysfunction

cognitive disorders

Authors:

Akhmedova A.A.

Pirogov Russian National Research Medical University (Pirogov University)

Ushanova F.O.

Pirogov Russian National Research Medical University (Pirogov University)

ORCID: 0000-0001-5512-6899

Demidova T.Yu.

Pirogov Russian National Research Medical University (Pirogov University)

ORCID: 0000-0001-6385-540X

Received:

26.09.2024

Accepted:

10.10.2024

List of references:

Dementia. Fact sheet N362. March 2015. https://www.who.int/mediacentre/factsheets/fs362/en/
Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64-74. https://doi.org/10.1016/S1474-4422(05)70284-2
Wong RH, Scholey A, Howe PR. Assessing premorbid cognitive ability in adults with type 2 diabetes mellitus--a review with implications for future intervention studies. Curr Diab Rep. 2014;14(11):547. https://doi.org/10.1007/s11892-014-0547-4
Sachdev PS, Lipnicki DM, Kochan NA, et al. The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS One. 2015;10(11):e0142388. https://doi.org/10.1371/journal.pone.0142388
Chatterjee S, Peters SA, Woodward M, et al. Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. Diabetes Care. 2016;39(2):300-307. https://doi.org/10.2337/dc15-1588
Zilliox LA, Chadrasekaran K, Kwan JY, et al. Diabetes and Cognitive Impairment. Curr Diab Rep. 2016;16(9):87. https://doi.org/10.1007/s11892-016-0775-x
Gaspar JM, Baptista FI, Macedo MP, et al. Inside the Diabetic Brain: Role of Different Players Involved in Cognitive Decline. ACS Chem Neurosci. 2016;7(2):131-142. https://doi.org/10.1021/acschemneuro.5b00240
Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci. 2008;9(1):36-45. https://doi.org/10.1038/nrn2294
Nuckols CC. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Philadelphia: American Psychiatric Association. 2013.
Benarroch EE. NMDA receptors: recent insights and clinical correlations. Neurology. 2011;76(20):1750-1757. https://doi.org/10.1212/WNL.0b013e31821b7cc9
Skeberdis VA, Lan J, Zheng X, et al. Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci USA. 2001;98(6):3561-3566.
de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(1):35-66. https://doi.org/10.2174/156720512799015037
Calvo-Ochoa E, Arias C. Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer’s disease: studies in animal models. Diabetes Metab Res Rev. 2015;31(1):1-13. https://doi.org/10.1002/dmrr.2531
Golpich M, Amini E, Hemmati F, et al. Glycogen synthase kinase-3 β (GSK-3β) signaling: implications for Parkinson’s disease. Pharmacol Res. 2015;97:16-26. https://doi.org/10.1016/j.pharmthera.2014.11.016
Nagao M, Hayashi H. Glycogen synthase kinase-3β is associated with Parkinson’s disease. Neurosci Lett. 2009;449:103-107. https://doi.org/10.1016/j.neulet.2008.10.104
Su B, Wang X, Zheng L, et al. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta. 2010;1802(1):135-142. https://doi.org/10.1016/j.bbadis.2009.09.013
Ostroumova OD, Surkova EV, Chikh EV, et al. Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs. Diabetes mellitus. 2018;21(4):307-318. (In Russ.). https://doi.org/10.14341/DM9660
Cognitive disorders in elderly and senile patients. Clinical recommendations of the Ministry of Health of the Russian Federation. Year of approval: 2020. (In Russ.).
Breton A, Casey D, Arnaoutoglou NA. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatry. 2019;34(2):233-242. https://doi.org/10.1002/gps.5016
Belleville S, Fouquet C, Hudon C, et al. Neuropsychological Measures that Predict Progression from Mild Cognitive Impairment to Alzheimer’s type dementia in Older Adults: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2017;27:328-353. https://doi.org/10.1007/s11065-017-9361-5
Dardenne S, Delrieu J, Sourdet S, et al. Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. J Alzheimers Dis. 2017;60(4):1567-1578.
Kravitz E, Schmeidler J, Schnaider Beeri M. Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies. Endocrinol Metab Clin North Am. 2013;42(3):489-501. https://doi.org/10.1016/j.ecl.2013.05.009
Dye L, Boyle NB, Champ C, et al. The relationship between obesity and cognitive health and decline. Proc Nutr Soc. 2017;76(4):443-454. https://doi.org/10.1017/S0029665117002014
Fiatarone Singh MA, Gates N, Saigal N, et al. The Study of Mental and Resistance Training (SMART) study—resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. J Am Med Dir Assoc. 2014;15(12):873-880. https://doi.org/10.1016/j.jamda.2014.09.010
Valente T, Gella A, Fernàndez-Busquets X, et al. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis. 2010;37(1):67-76. https://doi.org/10.1016/j.nbd.2009.09.008
Launer LJ, Miller ME, Williamson JD, et al. ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10(11):969-977. https://doi.org/10.1016/S1474-4422(11)70188-0
Shemesh E, Rudich A, Harman-Boehm I, et al. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab. 2012;97(2):366-376. https://doi.org/10.1210/jc.2011-1802
Morris JK, Vidoni ED, Mahnken JD, et al. Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin. Neurobiol Aging. 2016;39:19-24. https://doi.org/10.1016/j.neurobiolaging.2015.11.005
Erus G, Battapady H, Zhang T, et al. Spatial patterns of structural brain changes in type 2 diabetic patients and their longitudinal progression with intensive control of blood glucose. Diabetes Care. 2015;38(1):97-104. https://doi.org/10.2337/dc14-1196
Hanyu H, Sato T, Kiuchi A, et al. Pioglitazone improved cognition in a pilot study on patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009;57(1):177-179. https://doi.org/10.1111/j.1532-5415.2009.02067.x
Hölscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm. 2010;84:331-354. https://doi.org/10.1016/B978-0-12-381517-0.00013-8
Abbatecola AM, Lattanzio F, Molinari AM, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706-1711. https://doi.org/10.2337/dc09-2030

Close metadata